Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2005

View Archived Issues

GRN-163L suppresses human hepatoma growth in mice

Anticocaine antibody prevents death in a model of cocaine overdose

Eight-day oseltamivir dosing more effective than five-day against H5N1 influenza virus in mice

Farnesyltransferase inhibitors show promise for treating progeria

Nanobodies may substitute monoclonal antibodies

AVE-7688 reduces renal fibrosis in COL4A3-/- mice

AlphaRx completes development of vancomycin delivered with nanoparticle delivery platform

Alnylam Pharmaceuticals updates product pipeline

Xoma signs manufacture agreement for Cubist's HepeX-B biologic

Kereos raises funds to support clinical evaluation of MRI agents and therapeutics

Vion initiates solid tumor clinical development program with Cloretazine

Beta-2 adrenergic agonist carmoterol interacts positively with budesonide and tiotropium

Survival benefits of MEDI-522 in advanced melanoma patients

Ruboxistaurin improves renal function in patients with type 2 diabetes and nephropathy

Phase II data on rEV-131 in seasonal allergic rhinitis

Vyteris' Actyve transdermal drug delivery technology shows promise in phase I

Genaissance and Otsuka enter genetic markers research alliance

GSK's Zefix approved in Japan for HBV-associated cirrhosis

XTLbio licenses anti-HCV compounds and technology from VivoQuest

New therapeutic agents disclosed for respiratory disorders

Tripep advances alpha-HGA to phase I/II trial for HIV

Recent patents cover novel treatments for neurological disorders

Cipralex receives European approval for generalized anxiety disorder

Triglyceride reducing agents emerge from Esteve R&D

Studies reveal efficacy of Lanreotide Autogel in acromegaly patients

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...